trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['enhertu', 'pace a', 'daiichi', 'astrazeneca']
. and s enhertu looks set to disrupt the her2 space again, with new data at #asco23 showing a 37% response rate across a wide range of her2-positive tumours 
https://t.co/O0ZJQGuINh, and its digital magazine Deep Dive, is a leading online destination for healthcare and pharmaceutical industry news, insight and debate